Physiotensis, 0.4 mg 28 pcs

An antihypertensive agent. The mechanism of action of moxonidine is associated mainly with its effect on central parts of BP regulation. Moxonidine is an agonist of mainly imidazoline receptors.

With excitation of the above receptors of the neurons of the solitary tract, moxonidine through the system of inhibitory interneurons promotes inhibition of the activity of the vasomotor center and thus – reduction of descending sympathetic effects on the cardiovascular system. BP (systolic and diastolic) decreases gradually.

Moxonidine differs from other sympatholytic hypotensive agents in its lower affinity for α₂-adrenoreceptors, which explains the lower likelihood of developing sedative effects and dry mouth.

Moxonidine increases insulin sensitivity index (compared with placebo) by 21% in patients with obesity, insulin resistance and moderate arterial hypertension.

Indications

Arterial hypertension.

Pharmacological effect

Antihypertensive agent. The mechanism of action of moxonidine is associated mainly with its effect on the central links of blood pressure regulation. Moxonidine is an agonist primarily at imidazoline receptors.

By stimulating these receptors of solitary tract neurons, moxonidine, through a system of inhibitory interneurons, helps to inhibit the activity of the vasomotor center and thus reduce the descending sympathetic influences on the cardiovascular system. Blood pressure (systolic and diastolic) decreases gradually.

Moxonidine differs from other sympatholytic antihypertensive drugs in its lower affinity for α2-adrenergic receptors, which explains the lower likelihood of developing sedation and dry mouth.

Moxonidine increases the insulin sensitivity index (compared to placebo) by 21% in patients with obesity, insulin resistance and moderate hypertension.

Special instructions

Particular caution must be exercised when using moxonidine in patients with first degree AV block (risk of developing bradycardia); severe coronary artery disease and unstable angina (insufficient experience); renal failure.

If it is necessary to cancel simultaneously taken beta-blockers and moxonidine, first cancel the beta-blockers and only after a few days – moxonidine.

There is currently no evidence that stopping moxonidine leads to an increase in blood pressure. However, abrupt cessation of moxonidine is not recommended; the dose should be reduced gradually over 2 weeks.

Impact on the ability to drive vehicles and operate machinery

During treatment, patients should be careful if they need to engage in potentially hazardous activities that require concentration and high speed of psychomotor reactions.

Active ingredient

Moxonidine

Composition

1 tab. Moxonidine 0.4 mg

Excipients:

lactose monohydrate – 95.6 mg,

povidone – 0.7 mg,

crospovidone – 3 mg,

magnesium stearate – 0.3 mg.

Shell composition:

hypromellose – 1.3 mg,

ethylcellulose – 1.2 mg,

macrogol – 0.25 mg,

talc – 0.875 mg,

red iron oxide dye (E172) – 0.125 mg,

titanium dioxide (E171) – 1.25 mg.

Contraindications

Severe bradycardia (less than 50 beats/min), CVS, AV block II and III degrees, acute and chronic heart failure, lactation (breastfeeding), children and adolescents under 18 years of age, increased sensitivity to moxonidine.

Side Effects

From the side of the central nervous system: often – headache, dizziness (vertigo), drowsiness; infrequently – fainting.

From the cardiovascular system: infrequently – marked decrease in blood pressure, orthostatic hypotension, bradycardia.

From the digestive system: very often – dry mouth; often – diarrhea, nausea, vomiting, dyspepsia.

From the skin and subcutaneous tissues: often – skin rash, itching; infrequently – angioedema.

From the mental side: often – insomnia; infrequently – nervousness.

From the organ of hearing and labyrinthine disorders: infrequently – ringing in the ears.

From the musculoskeletal system: often – back pain; infrequently – pain in the neck.

From the body as a whole: often – asthenia; infrequently – peripheral edema.

Interaction

The combined use of moxonidine with other antihypertensive drugs leads to an additive effect.

Tricyclic antidepressants may reduce the effectiveness of centrally acting antihypertensive drugs, so their use together with moxonidine is not recommended.

Moxonidine may enhance the effect of tricyclic antidepressants, tranquilizers, ethanol, sedatives and hypnotics.

Moxonidine may moderately improve impaired cognitive function in patients receiving lorazepam.

Moxonidine may enhance the sedative effect of benzodiazepine derivatives when administered simultaneously.

Moxonidine is released by tubular secretion. Therefore, its interaction with other drugs released by tubular secretion is not excluded.

Manufacturer

Nobel Almaty Pharmaceutical Factory JSC, Kazakhstan